A single path from strain to scaleUnder the agreement, Acies Bio will handle the steps that turn Ginkgo’s host strains into working production systems. Acies Bio announced construction of a 30 m³ bioreactor in late 2025, with commissioning scheduled for the fourth quarter of 2026, an increase from its previous largest scale of 10 m³. © Ginkgo BioworksGinkgo produces its microbial strains through an automated laboratory that runs large numbers of genetic variations in parallel, screening for combinations of traits suited to manufacturing. Founded in 2006, Acies Bio works across microbial biotechnology, synthetic biology, and precision fermentation, with the deal positioning it as the commercial route to Ginkgo’s fungal host in Europe. This collaboration lets us offer customers a complete path, from strain access through process development and manufacturing, without needing to build fungal engineering capabilities in-house.”